z-logo
open-access-imgOpen Access
Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage
Author(s) -
Daou Badih J.,
Koduri Sravanthi,
Thompson B. Gregory,
Chaudhary Neeraj,
Pandey Aditya S.
Publication year - 2019
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/cns.13222
Subject(s) - medicine , subarachnoid hemorrhage , cilostazol , fasudil , vasospasm , nimodipine , cerebral vasospasm , clinical trial , intensive care medicine , anesthesia , milrinone , aspirin , signal transduction , biochemistry , chemistry , calcium , hemodynamics , rho associated protein kinase
Aneurysmal subarachnoid hemorrhage (aSAH) continues to be associated with significant morbidity and mortality despite advances in care and aneurysm treatment strategies. Cerebral vasospasm continues to be a major source of clinical worsening in patients. We intended to review the clinical and experimental aspects of aSAH and identify strategies that are being evaluated for the treatment of vasospasm. A literature review on aSAH and cerebral vasospasm was performed. Available treatments for aSAH continue to expand as research continues to identify new therapeutic targets. Oral nimodipine is the primary medication used in practice given its neuroprotective properties. Transluminal balloon angioplasty is widely utilized in patients with symptomatic vasospasm and ischemia. Prophylactic “triple‐H” therapy, clazosentan, and intraarterial papaverine have fallen out of practice. Trials have not shown strong evidence supporting magnesium or statins. Other calcium channel blockers, milrinone, tirilazad, fasudil, cilostazol, albumin, eicosapentaenoic acid, erythropoietin, corticosteroids, minocycline, deferoxamine, intrathecal thrombolytics, need to be further investigated. Many of the current experimental drugs may have significant roles in the treatment algorithm, and further clinical trials are needed. There is growing evidence supporting that early brain injury in aSAH may lead to significant morbidity and mortality, and this needs to be explored further.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here